Coherus Announces FDA Approval of YUSIMRY (adalimumab-aqvh)

Today, Coherus BioSciences, Inc. announced that the FDA approved YUSIMRY (adalimumab-aqvh), a biosimilar of AbbVie’s HUMIRA product.  YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis.  According to the press release, Coherus plans to launch YUSIMRY in the U.S. on or after July 1, 2023 based on the terms of its agreement with AbbVie.

YUSIMRY is the seventh biosimilar of HUMIRA to obtain FDA-approval. As previously reported, none of these biosimilars are yet on the U.S. market, as each biosimilar applicant has entered into a license agreement with AbbVie that permits the applicant to begin U.S. marketing only after a specified date in 2023.